Tinea Capitis

A study to compare the efficacy of daily therapy versus pulse therapy of oral itraconazole in the treatment of tinea capitis in children based on clinical, mycological and dermoscopic evaluation.

The goal of this observational study is to characterize the population pharmacokinetics (PPK) of terbinafine in pediatric patients with tinea capitis, evaluate its efficacy and safety, and identify covariates affecting drug disposition in Chinese children aged 2-18 years diagnosed with tinea capitis and treated with oral terbinafine. The main questions it aims to answer are: What are the terbinafine pharmacokinetic parameters (e.g., AUC, CL, V) in children with tinea capitis, and how do they differ from adult values? Which covariates (e.g., age, body weight, CYP enzyme activity, renal function) significantly influence inter-individual variability in terbinafine PK parameters? What is the clinical efficacy (based on TSSS reduction and mycological cure rate) and safety profile of terbinafine in this pediatric population? Participants will: Undergo oral terbinafine treatment according to weight-based dosing (62.5-250 mg daily). Concentration determination is carried out using the opportunistic sampling method. Complete clinical assessments (TSSS scoring) and mycological examinations (microscopy/culture) at baseline and follow-up visits. Undergo routine laboratory tests (liver/kidney function, hematology) to monitor safety.

Brief Summary (Plain Language Version) The goal of this observational study is to learn how well changes seen under a special microscope called a trichoscope (used to look at hair and scalp) match the success of treatment in children and adolescents with a scalp fungal infection called tinea capitis. The main questions it aims to answer are: Do changes in trichoscopic findings show when the fungal infection is cured? Does having more severe trichoscopic findings at the start mean that treatment will take longer or be less successful? Do different fungus types respond differently to the same treatment? Participants will: Be between the ages of 0 and 18 with confirmed tinea capitis based on lab tests (microscopy and/or culture) Receive an oral antifungal medicine called terbinafine for 4 weeks (dosing based on weight) Attend regular checkups every 4 weeks until both scalp appearance and lab tests show the infection is gone At each visit, participants will: Have their scalp examined using a trichoscope Provide scalp samples for fungal testing Be assessed for symptoms like itching, redness, and scaling The study will also look at how fast different signs on the scalp go away, and which of these signs are best at predicting whether the fungus is still present.